Haemophilia is a hereditary bleeding disorder. Credit: angellodeco via shutterstock.com.

Belief BioMed Group (BBM) has concluded dosing patients in its Phase III registrational trial evaluating BBM-H901 for the treatment of haemophilia B.

The multi-centre, single-arm, open and single-dose trial aims to assess the safety and efficacy of a single intravenous infusion of BBM-H901 in patients aged 18 years or above.

Related Company Profiles

View all

Patients with endogenous blood coagulation factor Ⅸ (FⅨ) activity ≤2 IU/dL are included in the trial.

The trial has so far completed its dose exploration and dose escalation portions, with positive efficacy and safety data.

The data also showed that 100% of patients stopped FⅨ treatment, while the annual bleeding rate (ABR) came down to zero.

See Also:

The level of coagulation factors grew significantly and was found in all patients, with a good safety profile and no serious adverse event observed.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

BBM-H901, an adeno-associated virus (AAV) gene therapy to treat haemophilia B, has been developed and produced by BBM’s wholly owned subsidiary Shanghai Belief-Delivery Biomed.

Haemophilia is a hereditary bleeding disorder and is primarily triggered by mutations in the coagulation factor Ⅷ or Ⅸ genes.

Belief BioMed co-founder, chairman and chief science officer Dr Xiao Xiao said: “We are pleased to see patient dosing has been successfully completed in the Phase III registrational trial of BBM-H901, the first blockbuster product independently developed and manufactured by BBM with the potential to become the first AAV gene therapy approved for marketing in China for prophylactic treatment of bleeding in adults with haemophilia B.

“Featuring ‘one-time administration and long-term effectiveness’, this innovative therapy will bring better survival benefits to patients.”

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.